MoonLake Immunotherapeutics (MLTX) News Today $46.07 -0.55 (-1.18%) Closing price 04:00 PM EasternExtended Trading$46.32 +0.26 (+0.55%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MLTX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Cantor Fitzgerald Forecasts MLTX FY2026 EarningsMoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of MoonLake Immunotherapeutics in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal expects that the companJune 10 at 8:56 AM | marketbeat.comMoonLake Immunotherapeutics (MLTX) Hosts Investor Meetings Amid Merger Speculation | MLTX Stock NewsJune 9 at 9:11 AM | gurufocus.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 17.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The instituJune 7 at 3:32 AM | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 3.9% - What's Next?MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 3.9% - Time to Sell?June 6, 2025 | marketbeat.comMoonLake Immunotherapeutics Breaks Above 200-Day Moving Average - Bullish for MLTXJune 5, 2025 | nasdaq.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Large Volume Increase - Here's WhyMoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Unusually-High Trading Volume - Here's WhyJune 4, 2025 | marketbeat.comWellington Management Group LLP Lowers Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX)Wellington Management Group LLP trimmed its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 48.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 99,0June 4, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Takes Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)Universal Beteiligungs und Servicegesellschaft mbH bought a new position in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 20,141 shares of the company's stock, valuJune 4, 2025 | marketbeat.comMoonLake Immunotherapeutics' (MLTX) Outperform Rating Reiterated at Royal Bank of CanadaJune 4, 2025 | americanbankingnews.comMoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma InterestJune 3, 2025 | seekingalpha.comConstellation and Meta, Merck, Snowflake: Trending TickersJune 3, 2025 | finance.yahoo.comMoonLake Immunotherapeutics Catapults On Rumored Merck TakeoverJune 3, 2025 | msn.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up - Here's What HappenedMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up - Time to Buy?June 3, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Outperform Rating from Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and set a $67.00 target price on shares of MoonLake Immunotherapeutics in a research note on Tuesday.June 3, 2025 | marketbeat.comMerck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: ReportJune 3, 2025 | benzinga.comMerck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: ReportJune 3, 2025 | finance.yahoo.comMoonLake Immunotherapeutics stock surges on FT report of Merck buyout talksJune 2, 2025 | investing.comMerck held talks to buy biotech MoonLake for over $3 billion, FT reportsJune 2, 2025 | reuters.comBank of America Corp DE Sells 76,559 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Bank of America Corp DE cut its stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 62.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 45,540 shares of the company's stock afterJune 2, 2025 | marketbeat.comNorthern Trust Corp Has $772,000 Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX)Northern Trust Corp lifted its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 161.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,261 shares of the company's stock aMay 31, 2025 | marketbeat.comEquities Analysts Set Expectations for MLTX Q2 EarningsMay 31, 2025 | americanbankingnews.comHC Wainwright Has Optimistic Outlook of MLTX Q2 EarningsMoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Equities research analysts at HC Wainwright lifted their Q2 2025 earnings estimates for MoonLake Immunotherapeutics in a research note issued on Tuesday, May 27th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earnMay 30, 2025 | marketbeat.comH.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PTMay 29, 2025 | finance.yahoo.comH.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PTMay 27, 2025 | insidermonkey.comBNP Paribas Financial Markets Takes $413,000 Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)BNP Paribas Financial Markets purchased a new stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 7,633 shares of the company's stock, valued at appMay 27, 2025 | marketbeat.comWoodline Partners LP Grows Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)Woodline Partners LP raised its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 26.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 293,535 shares of the company's stoMay 24, 2025 | marketbeat.comNuveen Asset Management LLC Boosts Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)Nuveen Asset Management LLC increased its stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 2.5% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 595,581 shares of the company's stock after purchasing an addMay 24, 2025 | marketbeat.comPoint72 Asset Management L.P. Invests $5.35 Million in MoonLake Immunotherapeutics (NASDAQ:MLTX)Point72 Asset Management L.P. purchased a new position in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 98,719 shares of the company's stock, valued at approximately $5,346,000. PoiMay 22, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Upgraded by Wolfe Research to Outperform RatingWolfe Research raised shares of MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 target price on the stock in a research note on Monday.May 21, 2025 | marketbeat.comWexford Capital LP Purchases 10,000 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Wexford Capital LP boosted its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 71.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,000 shares of the company's stMay 21, 2025 | marketbeat.comAmeriprise Financial Inc. Increases Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)Ameriprise Financial Inc. lifted its holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 28.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 204,373 shares of the company's stock after purchasing an additional 45,113 shares during the periodMay 21, 2025 | marketbeat.comWolfe Research Upgrades MoonLake Immunotherapeutics (MLTX)May 20, 2025 | msn.comWolfe Research Upgrades MoonLake Immunotherapeutics (MLTX) with a Bullish Outlook | MLTX Stock NewsMay 19, 2025 | gurufocus.comEnsign Peak Advisors Inc Sells 33,174 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Ensign Peak Advisors Inc reduced its stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 78.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,139 shares ofMay 19, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Moderate Buy" from AnalystsMoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and seven have assigned aMay 19, 2025 | marketbeat.comPolar Capital Holdings Plc Raises Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)Polar Capital Holdings Plc raised its stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 120.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,100,000 shares of the company's stock after purchasingMay 17, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by MPM Bioimpact LLCMPM Bioimpact LLC lessened its holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 9.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 315,230 shares of the company's stock after sellinMay 16, 2025 | marketbeat.comParadigm Biocapital Advisors LP Purchases 840,731 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Paradigm Biocapital Advisors LP grew its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 90.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,772,211 shares of the company'sMay 16, 2025 | marketbeat.comParkman Healthcare Partners LLC Has $2.94 Million Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)Parkman Healthcare Partners LLC reduced its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 47.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 54,294 shares of the company's stock afteMay 16, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Holdings Lowered by Schonfeld Strategic Advisors LLCSchonfeld Strategic Advisors LLC cut its position in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 95.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,911 shares of the company's stock after seMay 16, 2025 | marketbeat.comDimensional Fund Advisors LP Purchases Shares of 64,384 MoonLake Immunotherapeutics (NASDAQ:MLTX)Dimensional Fund Advisors LP purchased a new stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 64,384 shares of the company's stock, valued at approximately $3May 16, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Buy Rating from Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $66.00 price target on shares of MoonLake Immunotherapeutics in a report on Tuesday.May 15, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Releases Earnings Results, Beats Expectations By $0.13 EPSMoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.13.May 14, 2025 | marketbeat.comIntegral Health Asset Management LLC Sells 20,000 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Integral Health Asset Management LLC cut its stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 9.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 200,000 shares of the company's stock aftMay 14, 2025 | marketbeat.comMoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business UpdateMay 13, 2025 | finanznachrichten.deDecoding MoonLake Immunotherapeutics (MLTX): A Strategic SWOT InsightMay 13, 2025 | gurufocus.comMoonLake Immunotherapeutics: Promising Clinical Developments and Market Opportunities Justify Buy RatingMay 12, 2025 | tipranks.comMoonLake Immunotherapeutics (MLTX) Strengthens Financial Position with New Funding | MLTX Stock NewsMay 12, 2025 | gurufocus.comMoonLake Immunotherapeutics Q1 2025 Earnings: EPS of -$0. ...May 12, 2025 | gurufocus.comMoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a ...May 12, 2025 | gurufocus.com Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address MLTX Media Mentions By Week MLTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MLTX News Sentiment▼0.500.68▲Average Medical News Sentiment MLTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MLTX Articles This Week▼114▲MLTX Articles Average Week Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MRNA News Today VTRS News Today QGEN News Today BPMC News Today ROIV News Today RVMD News Today VRNA News Today BBIO News Today ELAN News Today GRFS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MLTX) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGet Ready for Elon Musk’s BIGGEST Comeback YetTesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored50-year legend: Here’s exact day stocks will crashGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MLTX Stock Free MLTX Stock Alerts